Edaravone

Edaravone
Clinical data
Trade names	Radicava, others
Other names	MCI-186
AHFS/Drugs.com	Monograph
MedlinePlus	a617027
License data	US DailyMed: Edaravone;
Pregnancy; category	AU: B3;
Routes of; administration	Intravenous, by mouth
ATC code	N07XX14 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name 5-methyl-2-phenyl-4H-pyrazol-3-one;
CAS Number	89-25-8 ;
PubChem CID	4021;
DrugBank	DB12243 ;
ChemSpider	3881 ;
UNII	S798V6YJRP;
KEGG	D01552 ;
ChEBI	CHEBI:31530 ;
ChEMBL	ChEMBL290916 ;
PDB ligand	W1P (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID9021130 ;
ECHA InfoCard	100.001.719
Chemical and physical data
Formula	C10H10N2O
Molar mass	174.203 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1N(/N=C(\C1)C)c2ccccc2;
	InChI InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3 ; Key:QELUYTUMUWHWMC-UHFFFAOYSA-N ;
	(verify)

Edaravone, sold under the brand name Radicava among others, is a medication used to treat stroke and amyotrophic lateral sclerosis (ALS). It is given by intravenous infusion and by mouth.

The most common side effects include bruising (contusions), problems walking (gait disturbances), and headaches.

The mechanism by which edaravone might be effective is unknown. The medication is known to be an antioxidant, and oxidative stress has been hypothesized to be part of the process that kills neurons in people with ALS.

The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.